GLP-1 Thyroid MTC Risk: What the Rodent Data, FDA Label, and Real-World Evidence Actually Mean for Patients

What the boxed warning actually says

Medullary thyroid carcinoma is a cancer that starts in the thyroid's C cells, the cells that make calcitonin. The GLP-1 boxed warning is about those cells.

The semaglutide label states that in rodents semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, that it is unknown whether the drug causes thyroid C-cell tumors, including MTC, in humans, and that the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [1]. The same boxed warning appears on Ozempic, Rybelsus and the Ozempic tablets [6][7].

The tirzepatide label describes a 2-year study in rats in which tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, adenomas and carcinomas, at clinically relevant plasma exposures [2][8]. Tirzepatide is a GIP and GLP-1 receptor agonist rather than a pure GLP-1 agonist, and it carries the same warning [2].

The warning and the MTC/MEN 2 contraindication appear on the semaglutide products (Ozempic, Wegovy injection and tablets, Rybelsus, Ozempic tablets) [1][6][7], on liraglutide and its insulin combination (Victoza, Saxenda, Xultophy) [9][10][11], on dulaglutide (Trulicity) [12], and on tirzepatide (Mounjaro, Zepbound) [2][8]. Byetta and Soliqua carry no boxed warning [4][5].

Orforglipron (Foundayo), the oral small-molecule GLP-1 tablet, has a boxed warning with different wording. Its label says orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents, but that it is active at the human GLP-1 receptor and the human relevance of GLP-1 receptor-dependent rodent tumors has not been determined. It is contraindicated in people with a personal or family history of MTC or MEN 2 [3].

What the rodent studies showed

Both labels describe the same pattern. Tumors appeared after long exposure (the semaglutide label specifies lifetime exposure in mice and rats; the tirzepatide label a 2-year rat study), they increased with dose and with duration, and they occurred at plasma exposures described as clinically relevant [1][2].

The one strand of human evidence the labels cite

The labels note that cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period, and that the data in those reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans [1][3].

Calcitonin in people taking these drugs

The most direct human dataset for this class is a 2011 pooled analysis of liraglutide trials published in the Journal of Clinical Endocrinology and Metabolism. Unstimulated serum calcitonin was measured at 3-month intervals for up to 2 years in over 5,000 people with type 2 diabetes or with obesity and no diabetes, assigned to liraglutide or control therapy. Basal mean calcitonin was at the low end of normal in every group and stayed low; at 2 years the estimated geometric means were no greater than 1.0 ng/L, well below the upper normal ranges. The proportion of people whose calcitonin rose above the clinically relevant cutoff of 20 ng/L was very low in all groups, with no consistent dose or time-dependent relationship and no consistent difference between treatment groups. The investigators concluded that the data do not support an effect of GLP-1 receptor activation on serum calcitonin in humans [13].

That is a calcitonin finding, not a cancer finding. The trials ran for up to 2 years and tested liraglutide, and the authors note that the long-term consequences of GLP-1 receptor agonist treatment are a subject of further studies [13].

Should calcitonin be monitored?

The semaglutide labels say that routine monitoring of serum calcitonin or use of thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with the drug. They give two reasons: serum calcitonin has low test specificity and thyroid disease has a high background incidence, so such monitoring may increase the risk of unnecessary procedures. The same section adds that a significantly elevated serum calcitonin may indicate MTC and that patients with MTC usually have calcitonin values greater than 50 ng/L; if calcitonin is measured and found elevated, the patient should be further evaluated, and thyroid nodules found on examination or neck imaging should also be further evaluated [1]. The tirzepatide and orforglipron labels carry the same language [2][3].

Who should not use these drugs

A personal or family history of MTC, or a diagnosis of MEN 2, is a listed contraindication on every product that carries the boxed warning [1][2][3].

Which symptoms the label tells patients to know

The labels instruct prescribers to counsel patients about the potential risk of MTC and to inform them of symptoms of thyroid tumors: a mass in the neck, dysphagia (trouble swallowing), dyspnea (shortness of breath) and persistent hoarseness [1][2]. Separately, the semaglutide labels say that an elevated serum calcitonin, or thyroid nodules noted on physical examination or neck imaging, should be further evaluated [1].

Compounded semaglutide and the warning

Compounded semaglutide has no FDA-approved label. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [14], so the boxed warning and the MTC/MEN 2 contraindication described here are label content for the approved products. HealthRX.com offers compounded semaglutide by prescription.